H.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics (INKT) to Neutral from Buy with a $35 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics announces publication of article on CAR-iNKT in Frontiers
- MiNK Therapeutics Enters $50M Sales Agreement with B. Riley
- Why Is MiNK Therapeutics Stock (INKT) Down 30% Today?
- MiNK Therapeutics Announces Clinical Trial Success
- William Blair downgrades MiNK on valuation after 700% rally